Tysabri Package Insert

TYSABRI Product Information - Tapp.com.au
Bdptysab11116 1 of 19 PRODUCT INFORMATION TYSABRI® (natalizumab, rmc) WARNING TYSABRI® is associated with an increased risk of progressive multifocal leucoencephalopathy (PML), an opportunistic viral infection of the brain that may lead ... Fetch Document

Payment Policy | Natalizumab (Tysabri®) For Multiple ...
This payment policy documents the coverage determination for Natalizumab (Tysabri®) for Multiple Sclerosis and Crohn’s Disease. Natalizumab (Tysabri®) is a genetically engineered monoclonal antibody that is indicated for use in the treatment of relapsing forms for multiple sclerosis (MS) to reduce the frequency of exacerbations. ... Access This Document

PHARMACY POLICY STATEMENT - Caresource.com
05/10/2017 New policy for Tysabri created. Policy SRx-0041 archived. For diagnosis of CD: trial of Humira required. For RRMS and SPMS diagnoses trial of two formulary agents required. List of diagnoses considered not medically necessary was added. 12/06/2017 Age coverage expanded. References: 1. Tysabri [package insert]. ... Fetch Content

SPECIALTY GUIDELINE MANAGEMENT - Provider.carefirst.com
Tysabri SGM P2017 CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members. Tysabri [package insert]. Cambridge, MA: Biogen Idec, Inc; May 2016. ... Fetch Here

UPMC Health Plan POLICY AND PROCEDURE MANUAL
Program can prescribe and receive Natalizumab (Tysabri) and only certain pharmacies and infusion sites authorized by the TOUCH prescribing program can dispense and infuse Natalizumab (Tysabri). III. PURPOSE The purpose of this policy is to define the Prior Authorization Process for Natalizumab (Tysabri). ... Read Here

WARNINGS AND PRECAUTIONS Hepatic Injury: Monitor Liver ...
1 INDICATIONS AND USAGE PLEGRIDY (peginterferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. ... Document Viewer

Package Leaflet: Information For The User - Medicines
Package leaflet: Information for the user Gilenya 0.25 mg hard capsules Gilenya 0.5 mg hard capsules fingolimod This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. ... Access Full Source

Boxed Warning - Wikipedia
In the United States, a boxed warning (sometimes "black box warning", colloquially) is a type of warning that appears on the package insert for certain prescription drugs, so called because the U.S. Food and Drug Administration specifies that it is formatted with a 'box' or border around the text. ... Read Article

I. Requirements For Prior Authorization Of Tysabri
1. Tysabri package insert. Biogen Idec Inc, 2010 2. Goodin, DS et.al. “Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy ofNeurology” ... Fetch Document

HIGHLIGHTS OF PRESCRIBING INFORMATION AUBAGIO
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. ... Read Full Source

Tecfidera ® (dimethyl fumarate) Tysabri® (natalizumab) Lemtrada® (alemtuzumab) Mitoxantrone Preferred Product: Copaxone, Rebif, Avonex, Betaseron , Aubagio, and Gilenya are the preferred MS agents. 19. Zinbryta [package insert]. Cambridg e, MA: Biogen Idec Inc. May 2016 ... Retrieve Doc

Natalizumab - Wikipedia
Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is co-marketed by Biogen and Élan as Tysabri, Because of this association, the drug label and package insert accompanying the drug will be updated to include this information. ... Read Article

I. Requirements For Prior Authorization Of Tysabri
1. Tysabri package insert. Biogen Idec Inc, 2012 2. Goodin, DS et.al. “Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology” ... Content Retrieval

Tysabri (natalizumab) Injection Label
TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) (1.1) As monotherapy for the treatment of patients with relapsing forms of multiple ... Read Content

AETNA BETTER HEALTH®
Last Revised: 10/2017 Previous PARP Approval: 12/2016 Current PARP Approval: 11/2017 Patient has a diagnosis of relapsing form of multiple sclerosis (i.e. relapsing-remitting or secondary progressive multiple sclerosis) OR Patient has Clinically Isolated Syndrome suggestive of MS (e.g., persons who have ... Visit Document

H.P. Acthar Gel
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Infantile spasms: H.P. Acthar Gel (repository corticotropin injection) is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ... Read More

Avonex Prescribing Information English Avonex Prescribing ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVONEX safely and effectively. See full prescribing information for AVONEX. ... Read Full Source

HIGHLIGHTS OF PRESCRIBING INFORMATION LETAIRIS For LETAIRIS
For all female patients, Letairis is available only through a restricted program called the Letairis Risk Evaluation and Mitigation Strategy (REMS) (5.2). -----INDICATIONS AND USAGE----- Letairis is an endothelin receptor antagonist indicated for the treatment ... Read More